Wealthfront Advisers LLC Acquires 4,834 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Wealthfront Advisers LLC raised its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 36.0% in the 4th quarter, Holdings Channel.com reports. The firm owned 18,254 shares of the biopharmaceutical company’s stock after buying an additional 4,834 shares during the quarter. Wealthfront Advisers LLC’s holdings in Alnylam Pharmaceuticals were worth $7,259,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Howard Capital Management Inc. increased its stake in Alnylam Pharmaceuticals by 2.9% in the 3rd quarter. Howard Capital Management Inc. now owns 854 shares of the biopharmaceutical company’s stock worth $389,000 after buying an additional 24 shares during the period. Frank Rimerman Advisors LLC increased its stake in Alnylam Pharmaceuticals by 2.0% in the 3rd quarter. Frank Rimerman Advisors LLC now owns 1,251 shares of the biopharmaceutical company’s stock worth $570,000 after buying an additional 24 shares during the period. Coastal Bridge Advisors LLC increased its stake in Alnylam Pharmaceuticals by 2.3% in the 3rd quarter. Coastal Bridge Advisors LLC now owns 1,097 shares of the biopharmaceutical company’s stock worth $500,000 after buying an additional 25 shares during the period. Meridian Financial Advisors LLC increased its stake in Alnylam Pharmaceuticals by 3.5% in the 3rd quarter. Meridian Financial Advisors LLC now owns 828 shares of the biopharmaceutical company’s stock worth $378,000 after buying an additional 28 shares during the period. Finally, First Horizon Corp increased its stake in Alnylam Pharmaceuticals by 20.7% in the 4th quarter. First Horizon Corp now owns 163 shares of the biopharmaceutical company’s stock worth $65,000 after buying an additional 28 shares during the period. Institutional investors own 92.97% of the company’s stock.

Insider Activity at Alnylam Pharmaceuticals

In other news, insider Melissa Mclaughlin sold 2,286 shares of the firm’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $330.42, for a total value of $755,340.12. Following the sale, the insider directly owned 9,443 shares in the company, valued at approximately $3,120,156.06. This trade represents a 19.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Jeffrey V. Poulton sold 2,242 shares of the firm’s stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $310.08, for a total transaction of $695,199.36. Following the completion of the sale, the executive vice president owned 59,802 shares in the company, valued at $18,543,404.16. This represents a 3.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 38,656 shares of company stock worth $12,370,696 over the last quarter. Corporate insiders own 0.86% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Jefferies Financial Group reaffirmed a “hold” rating and issued a $330.00 price target (down from $522.00) on shares of Alnylam Pharmaceuticals in a research note on Monday, March 16th. Weiss Ratings downgraded shares of Alnylam Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, April 6th. HC Wainwright reaffirmed a “buy” rating and issued a $510.00 price target on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 25th. Truist Financial reduced their price target on shares of Alnylam Pharmaceuticals from $515.00 to $505.00 and set a “buy” rating on the stock in a research note on Monday, April 13th. Finally, Wall Street Zen downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, March 21st. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $472.78.

Alnylam Pharmaceuticals Stock Down 0.3%

Shares of Alnylam Pharmaceuticals stock opened at $301.19 on Thursday. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.76 and a quick ratio of 2.71. Alnylam Pharmaceuticals, Inc. has a 1 year low of $245.96 and a 1 year high of $495.55. The firm’s 50-day moving average is $320.71 and its two-hundred day moving average is $377.92. The stock has a market cap of $40.19 billion, a price-to-earnings ratio of 176.13 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.43 by ($0.18). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The business had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $1.16 billion. During the same quarter in the previous year, the company earned ($0.65) earnings per share. The firm’s revenue was up 84.9% on a year-over-year basis. As a group, research analysts expect that Alnylam Pharmaceuticals, Inc. will post 6.75 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.